Tech Company Financing Transactions
Vedere Bio II Funding Round
Vedere Bio II closed a $77 million Series A funding round on 5/19/2021. Backers included Octagon Investments Fund, Atlas Venture and Casdin Capital.
Transaction Overview
Company Name
Announced On
5/19/2021
Transaction Type
Venture Equity
Amount
$77,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
300 Technology Sq. 8th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Vedere Bio II is pioneering beyond traditional gene therapy to not just slow vision loss from inherited retinal degenerations (IRDs) or dry age-related macular degeneration (dry AMD) with geographic atrophy (GA), but actually restore it.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Cyrus Mozayeni
Chief Operating Officer
Mark Gaffney
Browse more venture capital transactions:
Prev: 5/19/2021: DailyPay venture capital transaction
Next: 5/19/2021: LucidLink venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs